abiraterone acetate
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Steroid 17-alpha-hydroxylase/17,20 lyase.
- Target
- Steroid 17-alpha-hydroxylase/17,20 lyase
- Mechanism
- Cytochrome P450 17A1 inhibitor
pharma · Asthma · Osteoarthritis · AMRX
Amneal Pharma Europe
Amneal Pharma Europe Ltd
Amneal Pharma Europe drug portfolio — 80 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
400 Crossing Boulevard, Bridgewater, New Jersey 08807, US HQ
2002 Founded
7,179 Employees
Public company Type
AMRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 400 Crossing Boulevard, Bridgewater, New Jersey 08807, US
- Founded
- 2002
- Employees
- 7,179
- Programs
- 15
- Drugs
- 210
- Patents
- 32
Amneal Pharma Europe pipeline
Portfolio lens on 80 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Amneal Pharma Europe drug portfolio — 80 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.
- Target
- 5-hydroxytryptamine receptor 3A
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
US regulatory status: approved. Molecular target: Plasminogen.
- Target
- Plasminogen
- Mechanism
- Tissue-type plasminogen activator inhibitor
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
atazanavir sulfate
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 protease.
- Target
- Human immunodeficiency virus type 1 protease
- Mechanism
- Human immunodeficiency virus type 1 protease inhibitor
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Angiotensin-converting enzyme.
- Target
- Angiotensin-converting enzyme
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
bexarotene
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Retinoid X receptor.
- Target
- Retinoid X receptor
- Mechanism
- Retinoid X receptor agonist
-
bimatoprost
Sensory organs (S01)US regulatory status: approved. Molecular target: Prostaglandin F2-alpha receptor.
- Target
- Prostaglandin F2-alpha receptor
- Mechanism
- Prostanoid FP receptor agonist
-
brexpiprazole
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 1.
- Target
- Solute carrier family 12 member 1
- Mechanism
- Sodium-(potassium)-chloride cotransporter 2 inhibitor
-
US regulatory status: approved. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 1A.
- Target
- 5-hydroxytryptamine receptor 1A
- Mechanism
- Serotonin 1a (5-HT1a) receptor partial agonist
-
US regulatory status: approved. Molecular target: Phosphate.
- Target
- Phosphate
- Mechanism
- Phosphate sequestering agent
-
US regulatory status: approved. Mechanism: Mineral supplement.
- Mechanism
- Mineral supplement
-
US regulatory status: approved. Molecular target: Aromatic-L-amino-acid decarboxylase.
- Target
- Aromatic-L-amino-acid decarboxylase
- Mechanism
- DOPA decarboxylase inhibitor
-
US regulatory status: approved. Molecular target: Prostaglandin F2-alpha receptor.
- Target
- Prostaglandin F2-alpha receptor
- Mechanism
- Prostanoid FP receptor agonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to Amneal Pharma Europe in public FDA and regional records.
-
US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- D2-like dopamine receptor antagonist
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
clofarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: P2Y purinoceptor 12.
- Target
- P2Y purinoceptor 12
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
US regulatory status: approved. Molecular target: Opioid receptors; mu/kappa/delta.
- Target
- Opioid receptors; mu/kappa/delta
- Mechanism
- Opioid receptors; mu/kappa/delta agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
US regulatory status: approved. Molecular target: Dihydropteroate synthase.
- Target
- Dihydropteroate synthase
- Mechanism
- Dihydropteroate synthase 1 inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
dextromethorphan hydrobromide
Nervous system (N07)US regulatory status: approved. Molecular target: Glutamate receptor ionotropic, NMDA 2A.
- Target
- Glutamate receptor ionotropic, NMDA 2A
- Mechanism
- Glutamate [NMDA] receptor subunit epsilon 1 antagonist
-
US regulatory status: approved. Molecular target: Glutamate receptor ionotropic, NMDA 2A.
- Target
- Glutamate receptor ionotropic, NMDA 2A
- Mechanism
- Sigma opioid receptor agonist
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 1D.
- Target
- 5-hydroxytryptamine receptor 1D
- Mechanism
- Serotonin 1d (5-HT1d) receptor agonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Succinate-semialdehyde dehydrogenase, mitochondrial.
- Target
- Succinate-semialdehyde dehydrogenase, mitochondrial
- Mechanism
- Succinate semialdehyde dehydrogenase inhibitor
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
doxorubicin hydrochloride
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Matrix metalloproteinase-1 inhibitor
-
dronedarone
Cardiovascular system (C01)US regulatory status: approved. Mechanism: Sodium channel alpha subunit blocker.
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: Thrombopoietin receptor.
- Target
- Thrombopoietin receptor
- Mechanism
- Thrombopoietin receptor agonist
-
emtricitabine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
enalapril maleate
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Angiotensin-converting enzyme.
- Target
- Angiotensin-converting enzyme
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Potassium-transporting ATPase.
- Target
- Potassium-transporting ATPase
- Mechanism
- Potassium-transporting ATPase inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 1.
- Target
- Solute carrier family 12 member 1
- Mechanism
- Sodium-(potassium)-chloride cotransporter 2 inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.
- Target
- Prostaglandin G/H synthase 2
- Mechanism
- Cyclooxygenase-2 inhibitor
-
US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
US regulatory status: approved. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor antagonist
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M2.
- Target
- Muscarinic acetylcholine receptor M2
- Mechanism
- Muscarinic acetylcholine receptor M2 antagonist
-
US regulatory status: approved. Molecular target: Sodium channel protein type 5 subunit alpha.
- Target
- Sodium channel protein type 5 subunit alpha
- Mechanism
- Sodium channel protein type V alpha subunit blocker